These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 39078238)

  • 1. Dose optimization of β-lactam antibiotics in children: from population pharmacokinetics to individualized therapy.
    Ngougni Pokem P; Vanneste D; Schouwenburg S; Abdulla A; Gijsen M; Dhont E; Van der Linden D; Spriet I; De Cock P; Koch B; Van Bambeke F; Wijnant GJ
    Expert Opin Drug Metab Toxicol; 2024 Aug; 20(8):787-804. PubMed ID: 39078238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Towards precision medicine: Therapeutic drug monitoring-guided dosing of vancomycin and β-lactam antibiotics to maximize effectiveness and minimize toxicity.
    Cusumano JA; Klinker KP; Huttner A; Luther MK; Roberts JA; LaPlante KL
    Am J Health Syst Pharm; 2020 Jul; 77(14):1104-1112. PubMed ID: 32537644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic drug monitoring of β-lactam antibiotics in the ICU.
    Dhaese S; Van Vooren S; Boelens J; De Waele J
    Expert Rev Anti Infect Ther; 2020 Nov; 18(11):1155-1164. PubMed ID: 32597263
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A narrative review of predictors for β-lactam antibiotic exposure during empirical treatment in critically ill patients.
    Abdulla A; Ewoldt TMJ; Purmer IM; Muller AE; Gommers D; Endeman H; Koch BCP
    Expert Opin Drug Metab Toxicol; 2021 Apr; 17(4):359-368. PubMed ID: 33463382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. From Therapeutic Drug Monitoring to Model-Informed Precision Dosing for Antibiotics.
    Wicha SG; Märtson AG; Nielsen EI; Koch BCP; Friberg LE; Alffenaar JW; Minichmayr IK;
    Clin Pharmacol Ther; 2021 Apr; 109(4):928-941. PubMed ID: 33565627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimising β -lactam Dosing in Neonates: A Review of Pharmacokinetics, Drug Exposure and Pathogens.
    Fuchs A; Li G; van den Anker JN; Bielicki J
    Curr Pharm Des; 2017; 23(38):5805-5838. PubMed ID: 28950814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population pharmacokinetic models of first choice beta-lactam antibiotics for severe infections treatment: What antibiotic regimen to prescribe in children?
    Marsot A
    J Pharm Pharm Sci; 2020; 23():470-485. PubMed ID: 33227230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Individualized precision dosing approaches to optimize antimicrobial therapy in pediatric populations.
    Tu Q; Cotta M; Raman S; Graham N; Schlapbach L; Roberts JA
    Expert Rev Clin Pharmacol; 2021 Nov; 14(11):1383-1399. PubMed ID: 34313180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study protocol for ADAPT-TDM: A beta-lactam antibiotic Dose AdaPtation feasibility randomised controlled Trial using Therapeutic Drug Monitoring.
    Pai Mangalore R; Chai MG; Pope J; Lee SJ; Padiglione A; Diehl A; Roberts L; Sim K; Rawson-Harris P; Wicha S; Schneider HG; Peel TN; Jenney A; Ayton D; Peleg AY; Udy AA
    BMJ Open; 2024 Jul; 14(6):e083635. PubMed ID: 38951004
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antibiotic Stewardship and Therapeutic Drug Monitoring of β-Lactam Antibiotics: Is There a Link? An Opinion Paper.
    Richter DC; Heininger A; Chiriac U; Frey OR; Rau H; Fuchs T; Röhr AC; Brinkmann A; Weigand MA
    Ther Drug Monit; 2022 Feb; 44(1):103-111. PubMed ID: 34857694
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Model-informed precision dosing of antimicrobial drugs in pediatrics: experiences from a pilot scale program.
    Velarde-Salcedo R; Pérez-González LF; Rodríguez-Báez AS; Arriaga-García FJ; Milán-Segovia RDC; Romano-Moreno S; Medellín-Garibay SE
    Eur J Pediatr; 2023 Sep; 182(9):4143-4152. PubMed ID: 37436522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combatting the Rising Tide of Antimicrobial Resistance: Pharmacokinetic/Pharmacodynamic Dosing Strategies for Maximal Precision.
    Chua HC; Tse A; Smith NM; Mergenhagen KA; Cha R; Tsuji BT
    Int J Antimicrob Agents; 2021 Mar; 57(3):106269. PubMed ID: 33358761
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic aspects of beta-lactam antibiotic therapy in intensive care unit patients: A one-center experience with TDM.
    Sadilová K; Halačová M; Černý D
    Ceska Slov Farm; 2020; 69(1):17-23. PubMed ID: 32460506
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variation in Target Attainment of Beta-Lactam Antibiotic Dosing Between International Pediatric Formularies.
    Gastine S; Hsia Y; Clements M; Barker CIS; Bielicki J; Hartmann C; Sharland M; Standing JF
    Clin Pharmacol Ther; 2021 Apr; 109(4):958-970. PubMed ID: 33521971
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of the practical impact of adjusting beta-lactam dosages based on therapeutic drug monitoring in critically ill adult patients: a systematic review and meta-analysis of randomized clinical trials and observational studies.
    Gulyás E; Horváth IL; Engh MA; Bunduc S; Dembrovszky F; Fehérvári P; Bánvölgyi A; Csupor D; Hegyi P; Karvaly GB
    Sci Rep; 2024 Apr; 14(1):7793. PubMed ID: 38565898
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics/Pharmacodynamics of β-Lactams and Therapeutic Drug Monitoring: From Theory to Practical Issues in the Intensive Care Unit.
    Williams P; Cotta MO; Roberts JA
    Semin Respir Crit Care Med; 2019 Aug; 40(4):476-487. PubMed ID: 31585474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Failure of target attainment of beta-lactam antibiotics in critically ill patients and associated risk factors: a two-center prospective study (EXPAT).
    Abdulla A; Dijkstra A; Hunfeld NGM; Endeman H; Bahmany S; Ewoldt TMJ; Muller AE; van Gelder T; Gommers D; Koch BCP
    Crit Care; 2020 Sep; 24(1):558. PubMed ID: 32933574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of β-lactam antibiotic therapeutic drug monitoring on dose adjustments in critically ill patients undergoing continuous renal replacement therapy.
    Economou CJP; Wong G; McWhinney B; Ungerer JPJ; Lipman J; Roberts JA
    Int J Antimicrob Agents; 2017 May; 49(5):589-594. PubMed ID: 28341612
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic/pharmacodynamic target attainment in critically ill renal patients on antimicrobial usage: focus on novel beta-lactams and beta lactams/beta-lactamase inhibitors.
    Gatti M; Pea F
    Expert Rev Clin Pharmacol; 2021 May; 14(5):583-599. PubMed ID: 33687300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections.
    Tängdén T; Ramos Martín V; Felton TW; Nielsen EI; Marchand S; Brüggemann RJ; Bulitta JB; Bassetti M; Theuretzbacher U; Tsuji BT; Wareham DW; Friberg LE; De Waele JJ; Tam VH; Roberts JA;
    Intensive Care Med; 2017 Jul; 43(7):1021-1032. PubMed ID: 28409203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.